3//SEC Filing
Horowitz Limited Partnership VIII 3
Accession 0001209191-20-054996
CIK 0001819790other
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 8:26 PM ET
Size
9.7 KB
Accession
0001209191-20-054996
Insider Transaction Report
Form 3
Horowitz Limited Partnership VIII
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (245,966 underlying)Series A Preferred Stock
→ Common Stock (1,434,790 underlying)- (indirect: By Trust)
Series A Preferred Stock
→ Common Stock (43,151 underlying) Series C Preferred Stock
→ Common Stock (71,427 underlying)- (indirect: By Trust)
Series B Preferred Stock
→ Common Stock (7,396 underlying)
Footnotes (4)
- [F1]The Series A Preferred Stock shall automatically convert into shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock"), on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Stock has no expiration date.
- [F2]The Series B Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date.
- [F3]The Series C Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series C Preferred Stock has no expiration date.
- [F4]The shares are held by the Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII.
Documents
Issuer
Tarsus Pharmaceuticals, Inc.
CIK 0001819790
Entity typeother
IncorporatedCA
Related Parties
1- filerCIK 0001827839
Filing Metadata
- Form type
- 3
- Filed
- Oct 14, 8:00 PM ET
- Accepted
- Oct 15, 8:26 PM ET
- Size
- 9.7 KB